July 28, 2018
Enzyvant announced today the appointments of Andrew Dawson to head human resources and Alex Tracy, PhD to lead development and manufacturing, enhancing the overall capabilities of the company
July 19, 2018
Enzyvant today announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company, to screen for mutations in the ASAH1 gene.
July 9, 2018
Enzyvant, announced today that it has initiated its rolling submission of a Biologics License Application (BLA) for RVT-802 to the U.S. Food and Drug Administration (FDA).
July 5, 2018
Enzyvant today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.
June 4, 2018
Enzyvant today announced the appointments of Alan Kimura, MD, PhD as Chief Medical Officer and Tamara Joseph, JD, LLM as General Counsel.
October 16, 2017
Global study aims to define the natural course of Farber disease
September 5, 2017
Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802
April 17, 2017
Enzyvant receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for RVT-802
February 28, 2017
Enzyvant is participating in rare disease day! Click below for a list of local events
January 9-11, 2017
Come meet us at “Rare in the Square” in Union Square, San Francisco
January 6, 2017
Enzyvant to develop a novel biologic therapy for the treatment of immunodeficiency in complete DiGeorge Syndrome